Scarica l'app Stockscreener
13.81
0.36%
0.05
Dopo l'orario di chiusura:
13.83
0.02
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$13.76
Aprire:
$13.46
Volume 24 ore:
2.84M
Relative Volume:
0.53
Capitalizzazione di mercato:
$10.72B
Reddito:
$220.00K
Utile/perdita netta:
$-1.21B
Rapporto P/E:
-8.6103
EPS:
-1.6039
Flusso di cassa netto:
$-387.48M
1 W Prestazione:
-9.44%
1M Prestazione:
-1.85%
6M Prestazione:
-18.96%
1 anno Prestazione:
-50.02%
Intervallo 1D:
$13.36
$14.07
Intervallo di 1 settimana:
$13.36
$15.63
Portata 52W:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.81 | 10.68B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale - Streetwise Reports
Summit Therapeutics schedules Q2 2026 results, operational update call - Bitget
Kalshi to allow bets on clinical trials, FDA decisions - marketscreener.com
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 - BioSpace
Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 - Moomoo
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal - Yahoo Finance
The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal - simplywall.st
Summit Therapeutics (SMMT) Partners with Biossil for Ridinilazole Sale - GuruFocus
Summit to sell antibiotic to Canada’s Biossil for up to $105M - MSN
Summit Therapeutics Inc. Signs Agreement to Sell Ridinilazole to Biossil, Inc - marketscreener.com
Summit Therapeutics sells ridinilazole to Biossil for $500k By Investing.com - Investing.com South Africa
Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to Biossil in Milestone Deal - citybiz
Summit Therapeutics (SMMT) Sells Ridinilazole to Biossil for Up to $105M - GuruFocus
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. - BioSpace
Price to earnings forward of Summit Therapeutics Inc – BMV:SMMT - TradingView
Summit Therapeutics sells ridinilazole to Biossil for $500k - Investing.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology - DirectorsTalk Interviews
Why is SMMT stock tumbling today? - MSN
Why (SMMT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Summit Therapeutics (SMMT) Q1 2025 earnings summary - Quartr
Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary - Quartr
Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Enterprise value to EBITDA forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Company Profile & Introduction - Moomoo
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If You Invested $1,000 in Summit Therapeutics Inc (SMMT) - Stock Titan
Understanding Momentum Shifts in (SMMT) - Stock Traders Daily
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering? - Sahm
Summit Therapeutics Inc Actuals & Estimates (NASDAQ:SMMT) - TradingView
Summit Therapeutics Inc Actuals & Estimates (BMV:SMMT) - TradingView
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics finance chief tops list of public CFO pay in 2025 - CFO.com
Bernstein raises Summit Therapeutics stock price target on trial outlook By Investing.com - Investing.com Australia
Bernstein raises Summit Therapeutics stock price target on trial outlook - Investing.com
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Insider Monkey
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT) - Seeking Alpha
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8 - Moomoo
Summit Therapeutics (SMMT) Q4 2025 earnings summary - Quartr
5 Most Promising Healthcare Stocks According to Wall Street Analysts - Insider Monkey
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):